See more : Sea Harvest Group Limited (SHG.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Dynavax Technologies Corporation (DVAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dynavax Technologies Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Hui Xian Real Estate Investment Trust (87001.HK) Income Statement Analysis – Financial Results
- China Tianrui Automotive Interiors Co., LTD (6162.HK) Income Statement Analysis – Financial Results
- Essentra plc (FLRAF) Income Statement Analysis – Financial Results
- Yes Bank Limited (YESBANK.NS) Income Statement Analysis – Financial Results
- Agree Realty Corporation (ADC-PA) Income Statement Analysis – Financial Results
Dynavax Technologies Corporation (DVAX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.dynavax.com
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 232.28M | 722.68M | 439.44M | 46.55M | 35.22M | 8.20M | 327.00K | 11.04M | 4.05M | 11.03M | 11.25M | 9.71M | 21.61M | 23.95M | 40.32M | 37.09M | 14.09M | 4.85M | 14.66M | 14.81M | 826.00K | 1.43M | 2.36M | 0.00 |
| Cost of Revenue | 50.17M | 262.15M | 173.57M | 13.91M | 19.39M | 21.80M | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 299.00K | 980.00K | 980.00K | 980.00K | 1.00M | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 182.12M | 460.53M | 265.87M | 32.64M | 15.83M | -13.60M | -867.00K | 11.04M | 4.05M | 11.03M | 11.25M | 9.71M | 21.32M | 22.97M | 39.34M | 36.11M | 13.09M | 4.15M | 14.66M | 14.81M | 826.00K | 1.43M | 2.36M | 0.00 |
| Gross Profit Ratio | 78.40% | 63.73% | 60.50% | 70.12% | 44.95% | -165.87% | -265.14% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 98.62% | 95.91% | 97.57% | 97.36% | 92.88% | 85.60% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 54.89M | 46.60M | 32.23M | 28.61M | 62.33M | 74.95M | 64.99M | 84.49M | 86.94M | 84.58M | 50.87M | 49.15M | 51.32M | 53.68M | 38.71M | 44.77M | 65.89M | 50.12M | 27.89M | 23.13M | 14.38M | 15.97M | 17.36M | 8.27M |
| General & Administrative | 152.95M | 131.41M | 100.16M | 79.26M | 48.72M | 64.77M | 27.37M | 37.26M | 22.18M | 17.76M | 26.87M | 28.16M | 17.57M | 16.88M | 15.75M | 15.46M | 18.29M | 14.84M | 9.26M | 8.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 24.76M | 26.27M | 31.76M | 7.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 152.95M | 131.41M | 100.16M | 79.26M | 74.99M | 64.77M | 27.37M | 37.26M | 22.18M | 17.76M | 26.87M | 28.16M | 17.57M | 16.88M | 15.75M | 15.46M | 18.29M | 14.84M | 9.26M | 8.54M | 4.21M | 4.12M | 4.53M | 3.45M |
| Other Expenses | 11.31M | 7.80M | 8.66M | 6.81M | 3.35M | -70.00K | -486.00K | -2.49M | 317.00K | 433.00K | -348.00K | -293.00K | 299.00K | 980.00K | 980.00K | 980.00K | 1.00M | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 219.15M | 178.01M | 132.38M | 107.86M | 137.32M | 139.72M | 93.55M | 121.75M | 109.12M | 102.34M | 77.74M | 77.31M | 69.19M | 71.54M | 55.43M | 61.21M | 85.19M | 65.65M | 37.15M | 31.67M | 18.59M | 20.09M | 21.89M | 11.72M |
| Cost & Expenses | 269.31M | 440.16M | 305.96M | 121.77M | 156.71M | 161.52M | 93.55M | 121.75M | 109.12M | 102.34M | 77.74M | 77.31M | 69.19M | 71.54M | 55.43M | 61.21M | 85.19M | 65.65M | 37.15M | 31.67M | 18.59M | 20.09M | 21.89M | 11.72M |
| Interest Income | 31.99M | 7.91M | 140.00K | 1.26M | 3.37M | 3.83M | 1.34M | 755.00K | 205.00K | 191.00K | 116.00K | 291.00K | 103.00K | 85.00K | 112.00K | 1.74M | 4.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.76M | 6.73M | 11.18M | 19.06M | 16.98M | 9.34M | 0.00 | 0.00 | 572.00K | 35.00K | 0.00 | 2.35M | 1.96M | 1.65M | 124.00K | 9.16M | 1.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.28M | 6.67M | 7.01M | 9.34M | 21.53M | 14.48M | 4.44M | 2.26M | 1.37M | 1.40M | 1.33M | 1.21M | 1.60M | 2.40M | 2.84M | 2.83M | 632.00K | 1.53M | 3.13M | 3.27M | 576.00K | 678.00K | 0.00 | -2.05M |
| EBITDA | 9.67M | 307.70M | 95.71M | -46.84M | -114.09M | -135.08M | -90.72M | -110.19M | -104.86M | -89.28M | -65.39M | -66.39M | -45.04M | -53.26M | -12.17M | -21.29M | -71.09M | -60.67M | -19.36M | -15.44M | -17.19M | -17.98M | -19.53M | -11.72M |
| EBITDA Ratio | 4.16% | 41.27% | 32.38% | -144.26% | -325.87% | -1,824.36% | -27,292.05% | -1,002.51% | -2,581.51% | -822.04% | -579.16% | -695.88% | -216.57% | -154.67% | -30.45% | -70.87% | -497.32% | -1,136.60% | -132.09% | -91.73% | -2,080.87% | -1,260.06% | -827.94% | 0.00% |
| Operating Income | -37.03M | 283.52M | 134.49M | -75.22M | -121.49M | -153.32M | -96.01M | -110.71M | -105.07M | -91.31M | -66.49M | -67.60M | -47.58M | -47.59M | -15.12M | -24.12M | -71.09M | -64.98M | -22.49M | -16.86M | -17.76M | -18.66M | -19.53M | -9.66M |
| Operating Income Ratio | -15.94% | 39.23% | 30.60% | -161.59% | -344.95% | -1,870.20% | -29,359.33% | -1,002.51% | -2,594.40% | -827.69% | -590.95% | -695.86% | -220.12% | -198.70% | -37.49% | -65.02% | -504.45% | -1,340.68% | -153.46% | -113.83% | -2,150.61% | -1,307.57% | -827.94% | 0.00% |
| Total Other Income/Expenses | 32.66M | 10.78M | -56.97M | -6.87M | -17.76M | -5.58M | 851.00K | -1.74M | -1.72M | 589.00K | -232.00K | -2.35M | -1.02M | -9.72M | -12.00K | -2.42M | 2.45M | 3.19M | 1.94M | 889.00K | -274.00K | 0.00 | 19.53M | 0.00 |
| Income Before Tax | -4.37M | 294.30M | 77.52M | -75.24M | -152.60M | -158.90M | -95.15M | -112.44M | -106.79M | -90.72M | -66.72M | -69.95M | -48.60M | -57.31M | -30.57M | -20.83M | -59.97M | -52.05M | -20.56M | -15.97M | -18.04M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1.88% | 40.72% | 17.64% | -161.63% | -433.29% | -1,938.27% | -29,099.08% | -1,018.24% | -2,636.89% | -822.35% | -593.01% | -720.08% | -224.84% | -239.28% | -75.81% | -56.15% | -425.54% | -1,073.90% | -140.26% | -107.82% | -2,183.78% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.02M | 1.14M | 808.00K | 16.54M | -1.20M | 3.76M | 1.45M | -3.01M | -476.00K | -936.00K | -116.00K | 851.00K | 1.02M | 9.72M | 0.00 | -3.29M | 372.00K | -8.75M | 0.00 | 0.00 | -686.00K | -621.00K | 18.41M | 17.06M |
| Net Income | -6.39M | 293.16M | 76.71M | -91.78M | -151.40M | -158.90M | -95.15M | -112.44M | -106.79M | -90.72M | -66.72M | -69.95M | -48.60M | -57.31M | -30.57M | -20.83M | -59.97M | -52.05M | -20.56M | -15.97M | -17.35M | -18.04M | -18.41M | -26.72M |
| Net Income Ratio | -2.75% | 40.56% | 17.46% | -197.15% | -429.87% | -1,938.27% | -29,099.08% | -1,018.24% | -2,636.89% | -822.35% | -593.01% | -720.08% | -224.84% | -239.28% | -75.81% | -56.15% | -425.54% | -1,073.90% | -140.26% | -107.82% | -2,100.73% | -1,264.05% | -780.50% | 0.00% |
| EPS | -0.05 | 2.32 | 0.62 | -0.91 | -2.10 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.40 | -4.10 | -3.88 | -6.95 | -7.57 | -5.23 | -15.09 | -16.10 | -7.93 | -7.54 | -96.88 | -106.04 | -122.91 | -225.90 |
| EPS Diluted | -0.05 | 1.97 | 0.54 | -0.91 | -2.10 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.40 | -4.10 | -3.88 | -6.95 | -7.57 | -5.23 | -15.09 | -16.10 | -7.93 | -7.54 | -96.24 | -106.04 | -122.91 | -225.90 |
| Weighted Avg Shares Out | 128.73M | 126.40M | 116.26M | 100.75M | 72.02M | 62.36M | 52.61M | 38.51M | 32.88M | 26.29M | 19.63M | 17.05M | 12.51M | 8.25M | 4.04M | 3.98M | 3.97M | 3.23M | 2.59M | 2.12M | 179.10K | 170.10K | 149.80K | 118.30K |
| Weighted Avg Shares Out (Dil) | 128.73M | 150.80M | 133.01M | 100.75M | 72.02M | 62.36M | 52.61M | 38.51M | 32.88M | 26.29M | 19.63M | 17.05M | 12.51M | 8.25M | 4.04M | 3.98M | 3.97M | 3.23M | 2.59M | 2.12M | 180.30K | 170.10K | 149.80K | 118.30K |
Dynavax Technologies Corporation (DVAX) Q3 2022 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Nicole Arndt - Senior Manager, IR Ryan Spencer - CEO Donn Casale - SVP, Commercial Rob Janssen - CMO Kelly MacDonald -...
Dynavax Reports Third Quarter 2022 Financial Results
Q3 2022 total revenue of $167.7 million, up 55% from $108.3 million for Q3 2021 HEPLISAV-B ® vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021 CpG 1018 ® adjuvant net product revenue of $126.3 million, up 50% from $84.3 million...
Dynavax Technologies (DVAX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Should Value Investors Buy Dynavax Technologies (DVAX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
The 7 Most Undervalued Long-Term Stocks to Buy Now
My task today is to find seven of the most undervalued long-term stocks to buy now. We need to determine two things before stock selection takes place.
Dynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual Conference
EMERYVILLE, Calif. , Oct. 14, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C.
3 Under-the-Radar Small-Cap Stocks With 100% Upside Potential
If under-the-radar small-cap stocks are your jam, I've got three selections from the S&P SmallCap 600 that might be right up your alley. The small-cap index is down 20.3% year to date.
Clover Provides Update on 2022 Corporate Milestones
-- Significant progress made on regulatory submissions to the China NMPA, the EMA, and the WHO for Clover's lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), with completion anticipated in Q4 2022 -- -- New data demonstrating superiority as a heterologous booster...
Are Investors Undervaluing Dynavax Technologies (DVAX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Bet on These 4 Biotech Stocks With Bright Prospects
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
Source: https://incomestatements.info
Category: Stock Reports